MRI contrast agent for molecular imaging of the HER2/neu receptor using targeted magnetic nanoparticles
- 29 June 2010
- journal article
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 13 (6) , 2285-2293
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cellsJournal of Nanoparticle Research, 2009
- Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathwaysBMC Cancer, 2008
- RETRACTED: Ultrasound enhances in vivo tumor expression of plasmid DNA by PEG-introduced cationized dextranJournal of Controlled Release, 2005
- Overview of tyrosine kinase inhibitors in clinical breast cancerEndocrine-Related Cancer, 2005
- Medical application of functionalized magnetic nanoparticlesJournal of Bioscience and Bioengineering, 2005
- Synthesis and surface engineering of iron oxide nanoparticles for biomedical applicationsBiomaterials, 2005
- RETRACTED: PEGylation enhances tumor targeting of plasmid DNA by an artificial cationized protein with repeated RGD sequences, Pronectin®Journal of Controlled Release, 2004
- Dextran–spermine polycation: an efficient nonviral vector for in vitro and in vivo gene transfectionGene Therapy, 2004
- MR molecular imaging of the Her‐2/neu receptor in breast cancer cells using targeted iron oxide nanoparticlesMagnetic Resonance in Medicine, 2003
- RETRACTED: Tumor targeting of gene expression through metal-coordinated conjugation with dextranJournal of Controlled Release, 2003